Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Why should I try to catch a falling knife? This stock market bubble is about to burst and the economy is going south. Watch and learn.
The incompetent anti-science religious tRUMP toady Mike Pence is in charge the the Coronavirus task force. His task will be to lie as much as possible.
Dow is down 1k points now. Buy the blood. Good luck to you!
I sold off my remaining PGNX shares today. If the merger is rejected. I will buy back in. Besides, I am happy to have even more cash on hand as the market meltdown due to the the slowing economy and the rising risk that the Coronavirus drives us into recession.
Good luck, I pulled the plug on PGNX.
Actually, the buyout price will be lower since LNTH stock price is lower. We are getting a higher percentage of the joint company that is worth less. It is also unusual that no value was given for the CVR.
* * $PGNX Video Chart 02-20-2020 * *
Link to Video - click here to watch the technical chart video
Yes Slightly better terms, even after all that push-back from the large shareholder group Velan.
This is disappointing news, at least to me. It looks like the PGNX/LNTH merger is going to go through after all albeit on slightly better terms for PGNX shareholders.
Lantheus and Progenics Agree to Amended Transaction Terms
https://www.otcmarkets.com/stock/PGNX/news/story?e&id=1536248
* * $PGNX Video Chart 12-23-2019 * *
Link to Video - click here to watch the technical chart video
PGNX 8-K and News
https://www.otcmarkets.com/filing/html?id=13808484&guid=lQWvUFjYHsOlYth
Progenics Pharmaceuticals stock soars 29% on news of positive results in prostate cancer drug trial
https://www.marketwatch.com/story/progenics-pharmaceuticals-stock-soars-29-on-news-of-positive-results-in-prostate-cancer-drug-trial-2019-12-23?mod=mw_quote_news
$PGNX short squeeze Progenics Pharmaceuticals Inc Nasdaq Pgnx Short Squeeze
The PGNX saga continues. All 3 stock advisory firms has now weighed in and all three have ripped PGNX management and recommended that the CEO and board be removed prior to any decision on the proposed buyout by LNTH. Glass is the last advisory board to weigh in and they were really harsh in their criticism so we will likely soon see the current incompetent self-serving CEO Baker and the BOD voted out. Check it out as a warning about how poor management can really damage a company.
https://finance.yahoo.com/news/glass-lewis-recommends-stockholders-vote-130000333.html
Good news for PGNX shareholders as ISS weighed in and supported ousting the current incompetent self-serving board and CEO.
https://finance.yahoo.com/news/iss-recommends-shareholders-vote-green-110000850.html
The battle over PGNX continues as Velan strikes back. PGNX CEO Baker and management are incompetent fools and apparently liars as well.
https://finance.yahoo.com/news/velan-responds-misleading-communications-progenics-210300965.html
LNTH is a trivial little company with no record of drug development. The incompetent PGNX BOD and CEO are in a panic mode as they try to give away PGNX to LNTH and in the process gain themselves massive amounts of new stock options. Disgusting.
Velan is trying to put into place an excellent BOD that has a record of success. Since Velan has some 11% of PGNX shares, their interests are far more aligned with PGNX shareholders than the current BOD. Vote the GREEN card to oust the incompetent greedy self-serving PGNX BOD and CEO. The next move after that is to reject the proposed LNTH buyout.
* * $PGNX Video Chart 10-02-2019 * *
Link to Video - click here to watch the technical chart video
News: $PGNX Velan Comments on Announced Sale of Progenics to Lantheus
Believes Company’s Board has Abandoned its Fiduciary Duties by Choosing to Sell Progenics at Massive Discount in Attempt to Prevent the Voices of Shareholders from Being Heard Views Progenics’ Potential Value Under Appropriate Leadership to be Substantially Higher Tha...
Got this from PGNX - Velan Comments on Announced Sale of Progenics to Lantheus
News: $PGNX Progenics Merger Investigation: Halper Sadeh LLP Announces Investigation into Whether the Sale of Progenics Pharmaceuticals, Inc. is Fair to Shareholders; Investors Are Encouraged to Contact the Firm - PGNX
NEW YORK, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) to Lantheus Holdings, Inc. (“Lantheus”) for 0.2502 shares of Lantheus stock for each share of Pr...
Find out more PGNX - Progenics Merger Investigation: Halper Sadeh LLP Announces Investigation into Whether the Sale of Progenics Pharmaceuticals, Inc. is Fair to Shareholders; Investors Are Encouraged to Contact the Firm - PGNX
News: $PGNX Why Lantheus Holdings Is Dropping Today
Shares of Lantheus Holdings (NASDAQ: LNTH) , a company focused on diagnostic medical imaging equipment and supplies , dropped 21% as of 10:35 a.m. EDT on Wednesday after the company announced that it is acquiring Progenics Pharmaceuticals (NASDAQ: PGNX) , a commercial-stage biotechnology ...
In case you are interested PGNX - Why Lantheus Holdings Is Dropping Today
News: $PGNX Lantheus to Acquire Progenics to Form a Leading Precision Diagnostics Imaging and Therapeutics Company
Highly Complementary Portfolio of Ultrasound and Radiopharmaceutical Diagnostics and Oncology Therapeutics Lantheus’ Proven Commercial, Manufacturing and Operational Excellence Well Positioned to Optimize the Combined Company’s Innovative Diagnostic and Radiopharmaceutic...
Find out more PGNX - Lantheus to Acquire Progenics to Form a Leading Precision Diagnostics Imaging and Therapeutics Company
They are selling the company at market price:)
Quote:
Progenics Shareholders to Receive 0.2502 Shares of Lantheus Common Stock for Each Share of Progenics Stock in All-Stock Transaction
What is the price?
Lantheus to Acquire Progenics to Form a Leading Precision Diagnostics Imaging and Therapeutics Company
https://www.otcmarkets.com/stock/PGNX/news/story?e&id=1445257
* * $PGNX Video Chart 08-21-2019 * *
Link to Video - click here to watch the technical chart video
News: $PGNX ISS Supports Velan's Call for Change by Recommending Stockholders Vote "Against" Progenics Pharmaceuticals Directors Peter Crowley and Michael Kishbauch
ALPHARETTA, Ga. , June 28, 2019 /PRNewswire/ -- Velan Capital, L.P. (together with the other participants in its solicitation, "Velan" or "we"), one of the largest stockholders of Progenics Pharmaceuticals, Inc. ("Progenics" or the "Company")(NASDAQ: PGNX), comprised of successful sp...
Find out more https://marketwirenews.com/news-releases/iss-supports-velan-s-call-for-change-by-recommending-stockholde-8431410.html
News: $PGNX Progenics Reiterates Targeted Directors' Indispensable Experience and Leadership Critical to the Company's Long-Term Success
Comments on ISS Report Urges Shareholders to Vote “FOR” All of the Company’s Qualified Directors on the WHITE Proxy Card NEW YORK, June 28, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) (“Progenics” or the “Company&...
Got this from https://marketwirenews.com/news-releases/progenics-reiterates-targeted-directors-indispensable-experienc-8430938.html
News: $PGNX Velan Clarifies Interactions with Progenics Pharmaceuticals' Board of Directors
ALPHARETTA, Ga. , June 28, 2019 /PRNewswire/ -- Velan Capital, L.P. (together with the other participants in its solicitation, "Velan" or "we"), one of the largest stockholders of Progenics Pharmaceuticals, Inc. ("Progenics" or the "Company")(NASDAQ:PGNX), comprised of successful specialt...
In case you are interested https://marketwirenews.com/news-releases/velan-clarifies-interactions-with-progenics-pharmaceuticals-boa-8428232.html
News: $PGNX Velan sets the Record Straight on Progenics Pharmaceuticals' Latest Misleading Statements
ALPHARETTA, Ga. , June 17, 2019 /PRNewswire/ -- Velan Capital, L.P. (together with the other participants in its solicitation, "Velan" or "we"), one of the largest stockholders of Progenics Pharmaceuticals, Inc. ("Progenics" or the "Company")(NASDAQ:PGNX), comprised of successful specialt...
In case you are interested https://marketwirenews.com/news-releases/velan-sets-the-record-straight-on-progenics-pharmaceuticals-latest-misleading-statements-8368304.html
And sell off 8.50 because....Well, we will...
This is a bargain but ATM machine is 'still in effect'
We'll get there eventually be patient
Im projecting about $8 pps in 2 weeks or less. Lets get the gainz bros
Read something interesting in the 10k. PGNX has a royalty stake in this company:
https://content.equisolve.net/cytodyn/news/2019-02-01_CytoDyn_Announces_Productive_Conference_Call_with__312.pdf
Relistor sales were up 88% over Q3 of 2017 to $32 million last quarter so it looks like the $10 million milestone for exceeding $100 million in sales in calendar year will be triggered. No word yet on when Azedra sales will ramp up.
All in all a good report for PGNX.
Relistor sales were up 88% over Q3 of 2017 to $32 million last quarter so it looks like the $10 million milestone for exceeding $100 million in sales in calendar year will be triggered. No word yet on when Azedra sales will ramp up.
All in all a good report for PGNX.
WOW what a head fake after ER. Took it from 5.60's close down to 4.7's and right back up and currently 5.7's LOL YIKES!!!
yes, horrible - plus the 2nd failed trial. This was obvious after topping out, as if some knew about it.
Might be lacking positives for now.
Need to add a 250 million shelf offering and 75 million with sale of around 13.6 million shares.
Every time I think they have enough cash they dillute some more. UGH!!!
Followers
|
59
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
796
|
Created
|
03/12/08
|
Type
|
Free
|
Moderators |
http://www.progenics.com/
http://finance.yahoo.com/q/ks?s=PGNX
Progenics Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutic products for the treatment of unmet medical needs of patients with debilitating conditions and life-threatening diseases in the United States. It primarily focuses on the areas of gastroenterology, virology, and oncology. The company's development programs and product candidates include methylnaltrexone-subcutaneous, which completed Phase 3 clinical trial for the treatment of opioid-induced constipation; methylnaltrexone-intravenous, which is under Phase 3 clinical trial for the management of post-operative ileus; and Methylnaltrexone-Oral, a Phase 2 clinical trial oral form for the treatment of opioid-induced constipation. It is also developing PRO 140 Phase 1b clinical trial, designed to block HIV infection by inhibiting virus-cell binding; ProVax, a vaccine product candidate for the prevention of HIV infection or therapeutic treatment for HIV-positive individuals; and GMK Vaccine, a therapeutic vaccine, which is in Phase 3 clinical trial for the prevention of recurrence of melanoma. In addition, the company engages in a research program to discover treatments for hepatitis C, a chronic liver disease that block viral entry into cells. Further, Progenics Pharmaceuticals, through a joint venture with Cytogen Corporation, is developing in vivo immuno-therapies for treatment of prostate cancer, including a human monoclonal antibody-drug conjugate directed against prostate-specific membrane antigen (PSMA). The company's PSMA vaccine is in Phase 1 clinical testing. It has a collaboration agreement with Wyeth Pharmaceuticals to develop and commercialize subcutaneous, intravenous, and oral forms of methylnaltrexone. The company was incorporated in 1986 and is based in Tarrytown, New York.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |